playars
lotto players
- Registrato
- 11/4/08
- Messaggi
- 8.306
- Punti reazioni
- 174
si deve continuare
da questo:
dal lontano 2007
http://www.finanzaonline.com/forum/otcbb-pinksheet/835983-bmsn.html
un quadretto di famiglia molto interessante
BMSN, through its subsidiary Regen BioPharma, is a partner with Benitec
BioPharma. We have licensed the rights to their cancer gene silencing technology and combined it with the patent we own from Dr. Min to create the second drug in our pipeline, dCellVax. dCellVax is intended as a treatment for breast cancer initially.
Benitec BioPharma's senior vice president of research and development, Dr. David Suhy, also recently became a board member of Regen BioPharma.
Check out these links as they pertain to our relationship with Benitec BioPharma and our dCellVax product:
Company Press Releases:
Regen BioPharma Inc. Licenses Cancer Gene Silencing Technology From Benitec BioPharma
Bio-Matrix Scientific Group Recruits RNA Interference Pioneer Dr. David Suhy to Regen BioPharma Inc.'s Scientific Advisor Board
Bio-Matrix Scientific Group's Subsidiary, Regen BioPharma Announces dCellVax Breast Cancer Immunotherapeutic Product
Regen BioPharma Contract with Benitec BioPharma:
http://www.sec.gov/Archives/edgar/data/1589150/000155479513000605/reg1009forms1ex10_12.htm
da questo:
dal lontano 2007
http://www.finanzaonline.com/forum/otcbb-pinksheet/835983-bmsn.html
un quadretto di famiglia molto interessante
BMSN, through its subsidiary Regen BioPharma, is a partner with Benitec
BioPharma. We have licensed the rights to their cancer gene silencing technology and combined it with the patent we own from Dr. Min to create the second drug in our pipeline, dCellVax. dCellVax is intended as a treatment for breast cancer initially.
Benitec BioPharma's senior vice president of research and development, Dr. David Suhy, also recently became a board member of Regen BioPharma.
Check out these links as they pertain to our relationship with Benitec BioPharma and our dCellVax product:
Company Press Releases:
Regen BioPharma Inc. Licenses Cancer Gene Silencing Technology From Benitec BioPharma
Bio-Matrix Scientific Group Recruits RNA Interference Pioneer Dr. David Suhy to Regen BioPharma Inc.'s Scientific Advisor Board
Bio-Matrix Scientific Group's Subsidiary, Regen BioPharma Announces dCellVax Breast Cancer Immunotherapeutic Product
Regen BioPharma Contract with Benitec BioPharma:
http://www.sec.gov/Archives/edgar/data/1589150/000155479513000605/reg1009forms1ex10_12.htm